CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Sunshine Lake Pharma Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Sunshine Lake Pharma Co Ltd
No. 1 Industrial North Road
Songshan Lake Park
Phone: +86 76922895888p:+86 76922895888 DONGGUAN, GNG  523808  China Ticker: 68876887
Business Summary
Sunshine Lake Pharma Co Ltd is a China-based company principally engaged in research and development, production and commercialization of pharmaceutical products. The Company focuses on innovative drugs and is also involved in modified new drugs, generic drugs and biosimilars. The Company’s anti-infective products include Kewei (oseltamivir phosphate), for the treatment of influenza (in particular, Type A and Type B influenza viruses), Dongweien (emitasvir phosphate), for the treatment of hepatitis C, and generic drugs for the treatment of infections caused by sensitive bacteria, namely Clarithromycin, Levofloxacin and Moxifloxacin Hydrochloride. The Company’s commercialized chronic disease treatment drugs primarily focus on the treatment of diabetes, hyperuricemia, hypertension and stomach acid related disease, including insulin products and generic drugs. The Company also focuses on therapeutic area of oncology.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024-----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board YingjunZhang 47 5/10/2024 1/19/2021
General Manager, Executive Director WenjiaLi 42 5/10/2024 1/19/2021
Deputy General Manager FangfangHuang 42 6/19/2023 6/19/2023
11 additional Officers and Directors records available in full report.

General Information
Number of Employees: 6,550 (As of 12/31/2024)
Outstanding Shares: 576,656,047 (As of 8/6/2025)
Stock Exchange: HKG
Fax Number: +86 76985370223


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, August 12, 2025